Pfizer Reaches Drug Pricing Deal to Share Revenue With HHS
Pfizer agrees to share overseas pharmaceutical revenue with the Department of Health and Human Services under a new pricing arrangement.
Pfizer has agreed to share revenue generated from overseas drug sales with the U.S. Department of Health and Human Services, according to a pricing deal that signals a notable shift in how major pharmaceutical companies may structure agreements with the federal government.
The arrangement reflects ongoing pressure on drugmakers to address pricing disparities between what American consumers pay for medications and the lower prices often available in foreign markets. Federal health officials have increasingly sought mechanisms to ensure that domestic patients benefit from the global commercial success of U.S.-developed pharmaceuticals.
Read more Fed Terminates Enforcement Action Against SNB Bancshares and Bank of Eufaula →
Details of the specific revenue-sharing formula and which drug products fall under the agreement were not immediately available. However, such deals typically involve manufacturers offering rebates, tiered pricing structures, or direct contributions tied to international sales volumes as a condition of continued federal market access or reimbursement eligibility.
The move comes amid sustained political focus on prescription drug costs, with both the executive branch and Congress pursuing a range of tools to lower out-of-pocket expenses for patients. Agreements of this nature could serve as a template for negotiations with other large pharmaceutical manufacturers if the Pfizer arrangement demonstrates measurable savings.
Continue reading at All News for the latest developments on this story.
